Ultragenyx Pharmaceutical
RARE
234 hedge funds and large institutions have $5.69B invested in Ultragenyx Pharmaceutical in 2021 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 95 increasing their positions, 70 reducing their positions, and 19 closing their positions.
84% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 19
36% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 70
6% more funds holding
Funds holding: 221 → 234 (+13)
0.98% more ownership
Funds ownership: 98.28% → 99.25% (+0.98%)
5% less capital invested
Capital invested by funds: $6.01B → $5.69B (-$325M)
89% less call options, than puts
Call options by funds: $874K | Put options by funds: $8.01M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$112M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$39.5M |
| 3 |
ClearBridge Investments
New York
|
+$33.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$30M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$19.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$239M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$24M |
| 3 |
CII
Capital International Inc
Los Angeles,
California
|
-$20.5M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$11.7M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$9.46M |
RARE Hedge Fund Activity: Q4 2021 in Review
234 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2021, worth a combined $5.69B — down 5.4% from $6.01B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new RARE positions and 19 closed out — a net gain of 16 holders — while 95 added to existing stakes and 70 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $112M. The largest seller was Capital Research Global Investors, cutting an estimated $239M.
- 234 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2021, up from 221 in Q3 2021.
- Funds reported $5.69B of Ultragenyx Pharmaceutical stock for Q4 2021, down 5.4% quarter-over-quarter.
- 35 funds opened new Ultragenyx Pharmaceutical positions in Q4 2021 and 19 closed out, a net change of +16 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q4 2021 was RTW Investments, an estimated $112M added.
- The largest Ultragenyx Pharmaceutical seller in Q4 2021 was Capital Research Global Investors, an estimated $239M sold.
Based on aggregated 13F filings for Q4 2021.